Itrasys 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole acts by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrasys 100 is effective against infections caused by dermatophytes, yeasts, and molds, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. The capsule formulation ensures optimal bioavailability when taken with food, facilitating adequate systemic absorption. Dosage and duration of therapy depend on the type, severity, and site of infection, and should be determined by a healthcare professional. Itrasys 100 is contraindicated in patients with hypersensitivity to itraconazole or other azole antifungals and should be used cautiously in individuals with hepatic impairment or congestive heart failure. Potential adverse effects include gastrointestinal disturbances, hepatotoxicity, and drug interactions due to its effect on cytochrome P450 enzymes. Regular monitoring of liver function and clinical response is recommended during therapy. Itrasys 100 Capsule should be prescribed and administered under medical supervision to ensure safety and efficacy.